Avacta Group (LON:AVCT) Shares Cross Above 200-Day Moving Average – Should You Sell?

Avacta Group Plc (LON:AVCT) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 68.39 and traded as high as GBX 72. Avacta Group shares last traded at GBX 69, with a volume of 862,553 shares.

Avacta Group Trading Up 0.7%

The firm has a market capitalization of £323.30 million, a PE ratio of -7.14 and a beta of 1.12. The company’s 50-day moving average price is GBX 72.33 and its 200-day moving average price is GBX 68.44. The company has a debt-to-equity ratio of 602.46, a quick ratio of 4.96 and a current ratio of 0.89.

Avacta Group (LON:AVCT) last posted its earnings results on Tuesday, May 19th. The biotechnology company reported GBX (9.27) EPS for the quarter. Avacta Group had a negative net margin of 33,961.06% and a negative return on equity of 2,929.47%. The business had revenue of GBX 11 million during the quarter. On average, sell-side analysts expect that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).